Ex parte VERMA et al. - Page 7



                Appeal No. 1999-1221                                                                          
                Application No. 08/342-242                                                                    

                construction because it cannot be said to constitute or explain a claim limitation.”          
                Pitney Bowes Inc. v. Hewlett Packard Co., 182 F.3d 1298, 1305, 51 USPQ2d                      
                1161, 1165-66 (Fed. Cir. 1999).                                                               
                      In the instant claims, it is an open question whether the preamble                      
                language (“method for identifying compounds which modulate signal transduction                
                in cells”) has any patentable weight.  The preamble language might limit the                  
                claimed method, for example, if the selection of compounds to be tested would                 
                depend on the anticipated effect of the compound on signal transduction.  On the              
                other hand, if any compound might have an effect on signal transduction, the                  
                preamble language might place no additional limits on the method defined in the               
                body of the claim.                                                                            
                      This claim construction issue depends on technical aspects of the                       
                disclosed method and therefore we leave its resolution to the examiner.  If the               
                examiner is uncertain what weight should be given to the above -quoted                        
                language, we remind him that claims are given their broadest reasonable                       
                interpretation consistent with the specification.  See, e.g., In re Morris, 127 F.3d          
                1048, 1054, 44 USPQ2d 1023, 1027 (Fed. Cir. 1997).                                            
                      We encourage the examiner, after resolving the claim construction issue,                
                to consider some of the references that are cited by the references relied on in              
                this appeal.  We attach copies of two papers that seem particularly relevant.                 
                Lamph appears to disclose a method comprising exposing cells that express jun                 
                to compounds including cycloheximide and TPA, and monitoring changes in the                   


                                                      7                                                       



Page:  Previous  1  2  3  4  5  6  7  8  9  10  Next 

Last modified: November 3, 2007